Secondary Acute Myeloid Leukemia

general

An acute myeloid leukemia arising from prior myelodysplastic syndrome, myeloproliferative neoplasm, or myelodysplastic/myeloproliferative neoplasm, or as a result of previous exposure to alkylating agents or topoisomerase II inhibitors.

81

Centers

178

Active Trials

$2.6B

Cancer Funding

Specific Cancer Types(4)

Top Centers for Secondary Acute Myeloid Leukemia(81)

Ranked by research excellence score (trials · grants · publications). Methodology →

#CenterScore
1
NCI Comprehensive
High-Volume Research Center
76.1
2
NCI Comprehensive
High-Volume Research Center
75.6
372.4
4
NCI Comprehensive
High-Volume Research Center
71.1
5
High-Volume Research Center
71.1
6
High-Volume Research Center
71.1
7
NCI Comprehensive
Active Research Program
67.7
8
NCI Comprehensive
Active Research Program
67.7
9
NCI Comprehensive
Active Research Program
67.7
10
NCI Comprehensive
Active Research Program
67.7
11
NCI Comprehensive
Active Research Program
67.7
12
NCI Comprehensive
Active Research Program
67.7
13
NCI Comprehensive
Active Research Program
67.7
14
Active Research Program
67.7
15
NCI Comprehensive
Active Research Program
58.3
16
NCI Comprehensive
Active Research Program
58.3
17
NCI Comprehensive
Active Research Program
58.3
18
NCI Comprehensive
Active Research Program
58.3
19
NCI Comprehensive
Active Research Program
58.3
20
NCI Comprehensive
Active Research Program
58.3
21
NCI Comprehensive
Active Research Program
58.3
22
NCI Comprehensive
Active Research Program
58.3
23
NCI Comprehensive
Active Research Program
58.3
24
NCI Comprehensive
Active Research Program
58.3
25
NCI Comprehensive
Active Research Program
58.3
26
NCI Clinical
Active Research Program
58.3
27
Active Research Program
58.3
28
NCI Comprehensive
Active Research Program
58.3
29
NCI Comprehensive
Active Research Program
58.3
30
Active Research Program
58.3
31
Active Research Program
58.3
32
Active Research Program
58.3
33
Active Research Program
58.3
34
Active Research Program
58.3
3539.6
3639.6
37
NCI Comprehensive
39.6
38
NCI Comprehensive
39.6
3939.6
40
NCI Comprehensive
39.6
41
NCI Comprehensive
39.6
4239.6
4339.6
4439.6
45
NCI Comprehensive
39.6
46
Masonic Cancer CenterMinneapolis, MN
NCI Comprehensive
39.6
4739.6
48
NCI Comprehensive
39.6
49
NCI Clinical
39.6
50
NCI Clinical
39.6
51
NCI Comprehensive
39.6
5239.6
53
Cedars-Sinai CancerLos Angeles, CA
39.6
54
NCI Comprehensive
39.6
5539.6
5639.6
57
Rutgers Cancer InstituteNew Brunswick, NJ
NCI Comprehensive
39.6
5839.6
5939.6
60
Fox Chase Cancer CenterPhiladelphia, PA
NCI Comprehensive
39.6
6139.6
6239.6
6339.6
6439.6
6539.6
6639.6
6739.6
6839.6
6939.6
7039.6
7139.6
72
BC CancerVancouver, BC
39.6
73
74
75
NCI Comprehensive
76
NCI Comprehensive
77
78
79
80
81

Research tier badges reflect trial volume, NIH grant funding, and publication impact — not clinical outcomes or patient satisfaction. Learn about our methodology →